LB Pharma seeks $228M in proposed IPO with hopes to be industry's first since February

LB Pharmaceuticals, a biotech developing a twist on the decades-old schizophrenia treatment amisulpride, estimates it could gain net proceeds of $228 million from a Nasdaq IPO. The New York-based biotech could garnish that amount if ...